Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4639-4647

  Bennett, Lunawati L ^a   Turcotte, Kelsey ^a  

^a UNION UNIVERSITY   (United States)

Author keywords

Eliglustat tartrate; Gaucher disease; Glucocerebrosidase; Glucosylceramide synthase; Substrate reduction therapy

Indexed keywords

ELIGLUSTAT; MIGLUSTAT; CERAMIDE GLUCOSYLTRANSFERASE; CYTOCHROME P450 2D6; ENZYME INHIBITOR; GLUCOSYLCERAMIDE; GLUCOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE;

BACKACHE; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; HUMAN; INCIDENCE; LIMB PAIN; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; PHARMACOGENETICS; PHENOTYPE;

ADULT; ANIMALS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; ENZYME INHIBITORS; GAUCHER DISEASE; GENOTYPE; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; HUMANS; PHARMACOGENETICS; PHENOTYPE; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84981531896     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S77760     Document Type: Review

References (77)

1. Mehta A. Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med. 2006;17: S2-S5.
2. Hollak CE. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid. 2012;7: 15-20.
3. Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011;104: 438-447.
4. Conradi NG, Kalimo H, Sourander P. Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease. Acta Neuropathol. 1988;75: 385-390.
5. Grabowski GA. Gaucher disease: lessons from a decade of therapy. J Pediatr. 2004;144: S15-S19.
6. Barneveld RA, Keijzer W, Tegelaers FP, et al. Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet. 1983;64: 227-231.
7. Aerts JM, Hollak C, Boot R, Groener A. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Tran R Soc Lond B Biol Sci. 2003;358: 905-914.
8. Pastores GM, Hughes DA. Gaucher disease. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1269/?report. Accessed June 8, 2015.
9. Zimran A, Elstein D. Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT, editors. Williams Hematology. 8th ed. New York, NY, USA: McGraw-Hill; 2010.
10. Lee JY, Lee BH, Kim GH, et al. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr. 2012;55: 48-53.
11. Martins AM, Valadares ER, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155: S10-S18.
12. National Gaucher Foundation Inc. Available from: http://www.gaucherdisease.org/. Accessed June 1, 2015.
13. National Organization of Rare Disorders. Gaucher disease. Available from: http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/12/viewFullReport. Accessed June 1, 2015.
14. Altarescu G, Schiffmann R, Parker CC, et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis. 2000;26: 285-290.
15. [No authors listed]. Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA. 1996;275: 548-553.
16. Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet. 1991;49: 855-889.
17. Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010;4: 299-213.
18. Harmanci O, Bayraktar Y. Gaucher disease: new developments in treatment and etiology. World J Gastroenterol. 2008;14: 3968-3973.
19. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisalofGaucher disease - diagnosis anddisease managementalgorithms. Am J Hematol. 2011;86: 110-115.
20. Beighton P, Goldblatt J, Sacks S. Bone involvement in Gaucher disease. In: Desnick R, Gatt S, Grabowski G, editors. Gaucher Disease: A Century of Delineation. New York, NY, USA: Alan R Liss; 1982.
21. Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ. Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes. Arch Intern Med. 2010;170: 1463-1469.
22. Mikosch P. Gaucher disease and bone: best practice and clinical research. Rheumatology. 2011;21: 665-681.
23. Wine E, Yaniv I, Cohen IJ. Hyper-immunoglobulinemia in pediatric onset type 1 Gaucher disease and effects of enzyme replacement. J Pediatr Hematol Oncol. 2007;29: 451-457.
24. Capablo JL, de Cabezón AS, Fraile J, Alfonso P, Pocovi M, Giraldo P. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry. 2008;79: 219-222.
25. Griffiths GM. Gaucher disease: forging a new path to the lysosomes. Cell. 2007;131: 647-649.
26. Dvir H, Harel M, McCarthy AA, et al. X-ray structure of human acid-beta glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 2003;4: 704-709.
27. KornfeldS. Structure and function of the mannose 6-phosphate/insulin like growth factor II receptors. Annu Rev Biochem. 1992;61: 307-330.
28. ReczekD, SchwakeM, SchröderJ, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta glucocerebrosidase. Cell. 2007;131: 770-783.
29. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Hematol. 2005;129: 178-188.
30. Aerts JM, Kallemeijn WW, Wegdam W, et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011;34: 605-619.
31. Beutler E, Kuhl W. The diagnosis of the adult type of Gaucher’s disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes. J Lab Clin Med. 1970;76: 747-755.
32. Zimran A. How I treat Gaucher disease. Blood. 2011;118: 1463-1471.
33. Aerts JM, Donker-Koopman WE, van der Vliet MK, et al. The occurrence of two immunologically distinguishable beta glucocerebrosidases in human spleen. Eur J Biochem. 1985;150: 565-574.
34. Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, TagerJM, Schram AW. Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta. 1986;158: 155-163.
35. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin Haematol. 1997;10: 691-709.
36. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, CoxTM. Pathologic gene expression in Gaucher disease: upregulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 2000;96: 1969-1978.
37. van Breemen MJ, Aerts JM, Sprenger RR, Speijer D. Potential artifacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities. Clin Chim Acta. 2008;396: 26-32.
38. Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher’s disease. Eur Cytokine Netw. 1999;10: 205-210.
39. van Breemen MJ, de Fost M, Voerman JS, et al. Increased plasma macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta levels in type 1 Gaucher disease. Biochim Biophys Acta. 2007;1772: 788-796.
40. Moller HJ, de Frost M, Aerts H, Hollak C, Noetrup SK. Plasma level of macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher’s disease. Eur J Haematol. 2004;72: 135-139.
41. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268: 25803-25810.
42. Owhashi M, Arita H, Hayai N. Identification of a novel eosinophil chemotactic cytokine (ECF-L) as a chitinase family protein. J Biol Chem. 2000;275: 1279-1286.
43. Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis. 2001;24 Suppl 2: 97-105.
44. DiRocco M, Giona F, Carubbi F, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica. 2008;93: 1211-1218.
45. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventions. Blood. 2004;103: 33-39.
46. Deegan B, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35: 259-267.
47. Boot RG, Verhoek M, Langeveld M, et al. CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis. 2006;29: 564-571.
48. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuropathic Gaucher disease with special reference to pregnancy, splenectomy, biphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis. 2008;31: 319-336.
49. Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013;8: e79732.
50. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf. Search word: velaglucerase alfa. Accessed July 24, 2015.
51. http://dailymed.nlm.gov/dailymed/lookup.cfm? Search word: taliglucerase alfa. Accessed December 28, 2012.
52. Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35: 613-620.
53. Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124: 46-60.
54. Buccoliero R, Futerman AH. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacol Res. 2003;47: 409-419.
55. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=817892d1-ee12-4632-85fc-57ccdf16d7b8. Search word: miglustat. Accessed July 24, 2015.
56. Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64: 514-522.
57. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci. 2004;25: 147-151.
58. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep. 2004;5: 777-782.
59. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999;274: 14662-14669.
60. McWachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91: 259-267.
61. Marshall J, McEachern KA, Chuang WL, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010;33: 281-289.
62. Pavlova EV, Archer J, Wang SZ, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol. 2015;235: 113-124.
63. Cox TM. Eliglustat tartrate, an orally glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Invest Drugs. 2010;11: 1169-1181.
64. US Food and Drug Administration. FDA approves new orphan drug to treat a form of Gaucher disease. August 19, 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302549.htm. Accessed July 12, 2015.
65. Genzyme Corporation. Cerdelga (eliglustat). Available from: http://cerdelga.com/pdf/cerdelga_prescribing-information.pdf. Accessed June 23, 2015.
66. Poole RM. Eliglustat: first global approval. Drugs. 2014;74: 1829-1836.
67. Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single dose, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51: 695-705.
68. Lukina E, Watman N, Arreguin EA, et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116: 893-899.
69. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (GENZ-112638) treatment: 2-year results of a Phase 2 study. Blood. 2010;116: 4095-4098.
70. Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment. Blood Cells Mol Dis. 2014;53: 274-276.
71. Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a Phase 2 trial of oral eliglustat. Skeletal Radiol. 2014;43: 1353-1360.
72. Mistry PK, Lukina E, Turkia HB, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1. JAMA. 2015;313: 695-706.
73. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilized on enzyme replacement therapy: a Phase 3, randomised, open-label non-inferiority trial. Lancet. 2015;385: 2355-2362.
74. Genzyme, A Sanofi Company. A study of eliglustat tartrate (Genz-112638) in patients with Gaucher disease (ENGAGE). Available from: http://www.clinicaltrials.gov/ct2/eliglusat. Accessed June 23, 2015.
75. Wenstup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004;104: 1253-1257.
76. Sanuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, LibermanUA. Amino hydroxy propylidene biphosphonate (APD) treatment improve the clinical skeletal manifestations of Gaucher’s disease. Pediatrics. 1994;94: 385-389.
77. Available from: http://www.goodrx.com/cerdelga. Accessed June 22, 2015.